Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Significance of Longitudinal Psoas Muscle Loss in Predicting the Maintenance Efficacy of Durvalumab Treatment Following Concurrent Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer: A Retrospective Study.
Kuno H, Nishioka N, Yamada T, Kunimatsu Y, Yoshimura A, Hirai S, Futamura S, Masui T, Egami M, Chihara Y, Takayama K. Kuno H, et al. Among authors: kunimatsu y. Cancers (Basel). 2024 Aug 30;16(17):3037. doi: 10.3390/cancers16173037. Cancers (Basel). 2024. PMID: 39272894 Free PMC article.
Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study.
Takeda T, Yamada T, Kunimatsu Y, Tanimura K, Morimoto K, Shiotsu S, Chihara Y, Okada A, Horiuchi S, Hibino M, Uryu K, Honda R, Yamanaka Y, Yoshioka H, Kurata T, Takayama K. Takeda T, et al. Among authors: kunimatsu y. Cancers (Basel). 2023 Feb 28;15(5):1543. doi: 10.3390/cancers15051543. Cancers (Basel). 2023. PMID: 36900334 Free PMC article.
Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study.
Morimoto K, Yamada T, Takeda T, Shiotsu S, Date K, Tamiya N, Goto Y, Kanda H, Chihara Y, Kunimatsu Y, Katayama Y, Iwasaku M, Tokuda S, Takayama K. Morimoto K, et al. Among authors: kunimatsu y. Target Oncol. 2023 Sep;18(5):657-665. doi: 10.1007/s11523-023-00991-5. Epub 2023 Aug 23. Target Oncol. 2023. PMID: 37610516
Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan.
Hibino M, Uryu K, Takeda T, Kunimatsu Y, Shiotsu S, Uchino J, Hirai S, Yamada T, Okada A, Hasegawa Y, Hiranuma O, Chihara Y, Kamada R, Tobe S, Maeda K, Horiuchi S, Kondo T, Takayama K. Hibino M, et al. Among authors: kunimatsu y. J Thorac Oncol. 2022 Aug;17(8):1002-1013. doi: 10.1016/j.jtho.2022.05.015. Epub 2022 Jun 22. J Thorac Oncol. 2022. PMID: 35752437 Free PMC article.
55 results